Novozymes and Janssen to evaluate Veltis half-life extension technology
Series of engineered human albumins could help reduce dosing frequency of drugs
Novozymes Biopharma has agreed a tie-up with Janssen Research & Development in which Janssen will evaluate Novozymes Biopharma’s engineered albumin-based Veltis technology for potential drug candidates.
Svend Licht, Senior Director, Novozymes Biopharma, said the newly named Veltis technology can be linked to a range of drug candidates and the agreement is central in the company's strategy to demonstrate its potential to facilitate greater control across many therapeutic fields.
The Veltis technology represents a series of engineered human albumins which, in combination with a drug candidate, offers the potential for tunable control of the therapeutic half-life. The extended half-life of the albumins opens the door to reducing the dosing frequency of drugs from daily to every two weeks or monthly.
'The Veltis platform is a transformative technology that offers real potential to revolutionise the delivery of treatments,' added Licht.
Novozymes says the technology enhances the pharmacokinetics of peptide and protein drugs, potentially reducing dosing frequency of therapeutics to monthly, while contributing additional benefits through decreased dosage levels and reduced toxicity.
